Yours, Mine, or Ours? Navigating Intellectual Property Ownership in the Non-Profit Life Sciences

September 17, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Add to Calendar 9/17/2019 8:00:00 AM 9/17/2019 10:00:00 AM Yours, Mine, or Ours? Navigating Intellectual Property Ownership in the Non-Profit Life Sciences

Providing a new therapy or medical device to patients who will benefit generally requires commercial development. Development strategies are informed in part by patent laws governing ownership of intellectual property (IP), a complex landscape that must be navigated by non-profit organizations focused on advancing the development of new therapies for unmet medical needs. Join us for a discussion of the opportunities and challenges that non-profit organizations face in developing an IP strategy that will foster their mission effectively. Topics to be considered include:

  • Defining appropriate IP ownership expectations when awarding research grants.
  • Balancing research institution expectations of royalty returns with overall development investments and healthcare costs.
  • Managing conflicts of interest to ensure that patient benefit and safety remain the top priority.
 MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
President and Head of Business Development at Cancer Research UK - Boston
Andrea has focused on partnering early stage life sciences technologies for over 15 years. Since 2008 she has been at Cancer Research UK - Boston, building relationships between Cancer Research UK and the biotech/pharma industry throughout the US. Prior to CRUK, Andrea was at MIT's Technology Licensing Office, where she engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the early employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she spent a further three years focused on alliance development in the US and Europe, until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a postdoctoral fellowship in Genetics Institute's Small Molecule Drug Discovery group.